Science and medicine are vital to the well-being of humankind. Yet for all the incredible advances science has made, the unfortunate reality is that a worrying fraction of biological research is not reliable. Erroneous results might arise by chance or because of scientists’ mistakes or ineptitude. Very occasionally, researchers may behave unethically and fabricate or inappropriately manipulate their data.

Inevitably, this can lead to untrustworthy research that misleads scientists and the public on questions integral to our health. Indeed, a recent study showed the results of several high-profile cancer papers could not be fully replicated. This problem is not unique to cancer, and studies on various other diseases have also not stood up to scrutiny from outside investigators. Finding ways to detect dubious results is therefore essential to protect the public’s well-being and maintain public trust in science.

Here, Grimes demonstrates a new tool called the ‘Ellipse of Insignificance’ for measuring the reliability of dichotomous studies which are commonly used in many branches of biomedical sciences, including clinical trials. These studies typically compare two groups: one which was subjected to a specific treatment, and a control group which was not. Statistical methods are then applied to estimate how likely it is that differences in the number of observed events between the groups are real or due to chance.

The tool created by Grimes explores what would happen to seemingly strong results if some of the events in both the control and experimental arm of the study are recoded. It then assesses how much nudging is needed to change the statistical outcome of the experiment: the more interventions the result can withstand, the more robust the experiment. Grimes tested the tool and showed that a study suggesting a link between miscarriage and magnetic field exposure was likely unreliable because shifting the outcomes of less than two participants would change the result.

Scientists could use the Ellipse of Insignificance tool to quickly identify misleading published results or potential research fraud. Doing this could benefit researchers and protect the public from potential harm. It may also help preserve research integrity, increase transparency, and bolster public trust in science.

Biomedical science is crucial for human well-being, but there is an increasing awareness that many published results are less robust than desirable (Ioannidis, 2005; Loken and Gelman, 2017; Grimes et al., 2018). In fields from psychology (Krawczyk, 2015) to cancer research (Errington et al., 2021), a substantial volume of research fails to replicate. There is an urgent need to address this, as spurious findings can not only obscure important research directions, but can even misinform potentially life-or-death decisions. While there are many reasons why published research might fail trustworthiness (including poorly conducted experiments, publish-or-perish pressure, and overt fraud in the form of data and image manipulation), inappropriate or misapplied statistical methods account for a large portion of misleading results. Even a properly performed statistical analysis may fail to adequately identify situations where data might lack robustness. p values are routinely misunderstood and misapplied, leading to confused research outputs (Altman and Krzywinski, 2017; Colquhoun, 2014; Halsey et al., 2015). Dichotomous outcome trials and studies are crucial in many avenues of biomedicine, from preclinical observational studies to randomized controlled trials. The essential principle is that they contrast experimental and control groups for some intervention, comparing the numbers positive for some specific endpoint in both arms. This is absolutely integral to modern medicine to ascertain significant differences, but some authors have voiced concern that seeming significant findings in these trials can often disappear with the recoding of even small numbers of patients from endpoint positive to negative in either arm. The fragility index (FI) is the measure of many subjects are required to change a trial outcome from statistical significance to not significant. It is calculated by recoding a patient or subject in the experimental group (or control group) from event to non-event, and employing Fisher’s exact test until significance is lost. The number of patients requiring this recoding for this to occur is the FI. The concept of FI has existed in various forms since at least the work of Feinstein, 1990, and in general the higher the FI is, the more robust an experiment is deemed. Applications of FI have shown some concerning results; in a study of 399 randomized controlled trials (RCTs) in high-impact medical journals, Walsh et al., 2014 found that median FI was 8 (range: 0–109), with 25% having FI $\le 3$. In 53% of these trials, numbers lost to follow-up exceeded FI. A meta-analysis of spinal surgery studies Evaniew et al., 2015 found a median FI of 2, with 65% of trials having loss to follow-up greater than FI. A review of critical care trials (Ridgeon et al., 2016) and 2018 review of phase 3 cancer trials (Del Paggio and Tannock, 2019a) both found median FIs of 2, and a 2020 review of epilepsy research (Das and Xaviar, 2020) yielded a median FI of 1.5. A recent fragility analysis of COVID-19 trials found that had a median FI of only 4, despite the large numbers of patients involved (Itaya et al., 2022). This suggests that many results are not robust, and teeter on the edge of statistical significance. While a very useful metric, FI has some substantial faults. There is considerable debate over whether is it appropriate for time-to-event cases (Bomze and Meirson, 2019; Desnoyers et al., 2019; Machado et al., 2019; Del Paggio and Tannock, 2019b). More directly, there is no simple FI cut-off metric that designates studies as either robust or fragile, though some authors suggest the fragility quotient (FQ) as an extension, the fraction of FI over sample size (Tignanelli and Napolitano, 2019). In addition, FI and FQ can also be computationally expensive to run, typically requiring multiple iterations of Fisher’s exact test to converge. As Fisher’s exact test relies on factorials, it is typically not suited to larger trials or studies. It is also implicitly considers only either control or experimental groups in isolation, even though it is possible that miscoding can occur in both cohorts. Nor does FI relate directly to test parameters between non-events and events, such as sensitivity or specificity. Many of these objections and counterpoints to them are discussed in recent work by Baer et al., 2021a. With FI and FQ becoming increasingly commonly reported in the literature, it is worthwhile to introduce a related, refined metric with new application. In this work, I introduce a geometric refinement of the concept underpinning FI which overcomes some difficulties associated with FI analysis, considering recoding in both control and experimental groups in tandem. This ellipse of insignificance (EOI) approach is exact and computationally inexpensive, yielding objective measures of experimental robustness. There are two major differences and situational advantages to such a formulation; firstly, it can handle huge data sets with ease and consider both control and experimental arms simultaneously, which traditional fragility analysis cannot. Previously, fragility has been typically considered in the case of relatively small numbers in RCTs, which as previous commentators have noted are often fragile by design. The method outlined here handles massive numbers with ease, rendering it suitable for analysis of observational trials, cohort studies, and general preclinical work, to detect dubious results and fraud. This sets it apart in both intention and application to existing measures, and makes it unique in this regard. Secondly, this methodology is not solely a new, robust FI; it also goes further by linking the concept of fragility to test sensitivity and specificity. This a priori allows an investigator to probe not only whether a result is arbitrarily fragile, but to truly probe whether consider certain results are even possible. This renders it less arbitrary than existent measures, as it ties directly statistically measurable quantities to stated results, and is sufficiently powerful to rule out suspect findings in many dichotomous trials and studies. It can accordingly be used to detect likely fraud or inappropriate manipulation of results if the statistical properties of the tests used are known. This is unfortunately highly relevant, as unsound or otherwise manipulated results have become an increasingly recognized problem in biomedical research, and means to detect them are vital. The EOI analysis outlined here for any $2\times 2$ dichotomous outcome trial or study, with an experimental arm consisting of $a$ subjects with endpoint positive outcomes and $b$ without, and a control arm with $c$ subjects with endpoint positive versus $d$ without. The EOI analysis outlined in the methodology section allows rapid determination of the effects of recoding in all arms simultaneously, and ties this explicitly to test sensitivity and specificity, with illustrative examples of application demonstrated.

The EOI approach is based upon the principles of a chi-squared analysis. Consider an experimental group containing $a$ participants with a given endpoint and $b$ participants without that endpoint. In the control group, there are $c$ participants with the given endpoint, and $d$ without. The total number of participants is given by $n=a+b+c+d$. For a 2 by 2 contingency table, the chi-squared statistic is given by

When this statistic is greater than a specified threshold, results are deemed significant and differences between the control and experimental groups considered indicative of real differences. The initial question this work concerns itself with is ascertaining how many patients or subjects would have to be recoded to transform an ostensibly significant result into one where the null hypothesis was not rejected. This recoding can be achieved two ways: by subtracting $x$ participants from $a$ (experimental group, endpoint positive) or by adding $y$ participants to $c$ (control group, endpoint positive). These configurations are given in Table 1.

Applying the same statistic outlined in Equation 1, with a threshold critical value for significance of ${\nu }_c$, the resulting identity is

This form can be expanded, with the resultant equation being a conic section (Grimes and Currell, 2018) of the form $A{x}^2+Bxy+C{y}^2+Dx+Ey+F=0$. This corresponds specifically to an inclined ellipse, with coefficients A–F given by

Any points on or in inside this EOI will fall below the threshold to reject the null hypothesis, and the ellipse is effectively the bound of all values of $x$ and $y$ sufficient to cause a loss of significance at a threshold critical value of ${\nu }_c$, calculated from the chi-squared distribution at a given level of significance with one degree of freedom.

FECKUP point and vector

Finding the minimum distance from the origin to the EOI allows us to ascertain the minimal error which would render results insignificant. To find this, we take the implicit derivative of the distance vector from the origin to this unknown point, and the implicit derivative of the equation of the inclined ellipse whose coefficients are given in Equations 3–8. Setting $y^{\prime }$ equal in both equations leads to the pair of simultaneous equations for the unknown point $(x_e,y_e)$ of

(9) $(2A{x}_e+B{y}_e+D)y_e-x_e(B{x}_e+2C{y}_e+E)=0$

(10) $A{x}_e^2+B{x}_e{y}_e+C{y}_e^2+D{x}_e+E{y}_e+F=0.$

Solving this results in a quartic equation, resulting in four solutions, one pair of which will be the minimum distance point $(x_e,y_e)$. This can be readily checked, and the solution pair will correspond to the absolute minimum pair value to lose significance at a given threshold. This resultant point and vector denotes the Fewest Experimental/Control Knowingly Uncoded Participants (FECKUP), with length $f_{min}$. An illustration of this is shown in Figure 1a. Accordingly, the points x_e and y_e can be understood as the resolution of vector $f_{min}$ in the experimental and control directions, respectively. If both experimental and control participants can be miscoded, the theoretical minimum number that could be miscoded before a seemingly significant result dissipated, $d_{min}$, is the sum of the opposite and adjacent lengths of the right-angled triangle formed by hypotenuse $f_{min}$. As there are only integer numbers of participants, it thus follows that

(11) $d_{min}=\lfloor |x_e|+|y_e|\rfloor .$

Figure 1

Download asset Open asset

If we instead only consider inaccuracies in the experimental group as possible, we may set $y=0$ and $x=x_i$ for the equation of the ellipse, yielding the quadratic identity $A{x}^2+Dx+F=0$, readily solvable to determine x_i. This is the point nearest the origin where the ellipse intercepts the x-axis. Conversely, we may consider a situation where only inaccuracies in the control group may exist. By similar reasoning, considering only inaccuracies in the control group yields a similar quadratic, $C{y}^2+Ey+F$ to yield y_i, the intercept of the ellipse with the y-axis. All these vectors are illustrated in Figure 1b, and are the maximum limits of miscoding theoretically possible before significance is lost.

The analysis presented here is a deterministic way to ascertain the fragility of a given dichotomous outcome study by considering experimental and control groups in concert. This method is geometrical in origin and computationally inexpensive. It also explicitly can relate outcome fragility to the sensitivity and specificity of tests employed when known, aiding clinicians and meta-researchers in interpreting the trustworthiness of a given study. Sample OCTAVE and MATLAB code and stand-alone Windows applications are provided to run the analysis outlined in this work, available in the electronic supplementary material. There are a number of limitations of this work that should be explicitly discussed, and caveats to be elucidated. The EOI analysis handles potential miscoding, but cannot be used to infer anything about patients or subjects lost to follow-up. This is a weakness of all FI/FQ methods, as it is not a priori knowable from reported data alone why patients dropped out, or why they might have atrophied from particular subgroups. Redaction bias (Grimes and Heathers, 2021b) can occur if subjects leave a particular subset at an elevated rate, and while beyond the scope of this work, it is important to realize that explicit connections between EOI/FI/FQ analysis and numbers lost to follow-up cannot be directly made. The method outlined is deterministic and rapid, but only currently applicable to dichotomous outcome trials and studies, and should be applied very cautiously to time-to-event data, where it may not be suitable. FI itself is also typically calculated using Fisher’s exact test, which well approximates a chi-squared test. However, for small trials, the p value derived from Fisher’s exact test can be discrepant from chi-squared result. When Fisher’s exact test produces a non-significant p value without any recoding, an FI of 0 results, suggesting a distinct lack of robustness of the underlying data. As EOI analysis is built upon chi-squared statistics, it is possible in edge cases of small numbers to have discordant results between EOI and Fisher’s exact test also. The chief advantage of the method outlined here, however, is that it handles extremely large data sets with ease. In large data sets, Fischer’s exact test breaks down due to its dependence on factorials, and a chi-squared approximation is more appropriate. This is fitting, given EOI is built upon the chi-square distribution. But the important caveat is that for rare events in small trials, an FI approach built upon Fisher’s exact test may be more appropriate (Baer et al., 2021a). The usage of FI/FQ itself remains contested in the literature, and one frequent objection is that the mere existence of a small FI might be an artefact of trial design (Walter et al., 2020). With clinical RCTs in particular, experimenters often design trials to minimize exposure of patients or subjects to as of yet unknown harms, while seeking to ensure enough of them participate so that clinically relevant causal effects can be reliably detected. From this vantage point, RCTs might be fragile ‘by design’. This view is countered by other authors Baer et al., 2021a who argue that there are no evidence p value distributions tend to cluster around the significance threshold after a sample size calculation, and that the FI in well-designed studies is not always low (Baer et al., 2021b). This work does not comment on the absolute applicability of the FI, but offers new metrics for quantification of results in context. More importantly, EOI analysis has definite application for dichotomous outcome results not derived just from fragile-by-design RCTs, but from ecological studies, cohort trials, and preclinical work which should in principle be far more resilient to investigation than RCTs. There is a less edifying but important reason why EOI analysis might be conducted – the detection of questionable research practices and fraud. While most scientists and clinicians operate ethically, poor conduct and inappropriate statistical manipulation can and do occur. By some estimates, up to three quarters of all biomedical science are affected by poor practice (Fanelli, 2009), casting doubt on results to the detriment of science and the public, often a consequence of publish-or-perish pressure (Grimes et al., 2018). During the COVID-19 pandemic, a number of dubious high-profile results have come to light, particularly on drugs like Ivermectin (Hill et al., 2022; Besançon et al., 2022). EOI analysis has a potential role in detecting manipulations that nudge results towards significance, and identifying inconsistencies in data. EOI analysis is perhaps ideal for this purpose, as it explicitly relates known test sensitivity and specificity to projected error tolerance, allowing detection of suspect results in even large data sets, as illustrated by the real examples in this work. Despite its caveats on usage, the FI has seen growing application in analysis of trial outcomes, and the EOI system presented here should allow this to be applied more thoroughly in a multidimensional way. Regardless of whether appropriate research practice has been observed or not, it is important to be able to estimate the soundness of results in biomedical science, to ascertain what level of confidence once can ascribe to them. This need has seen the recent resurgence of FI analysis, and the EOI analysis presented here can help undercover questionable results and experimental inconsistencies, with wide potential application in meta-research and reproducible research.

The paper is a modelling study and methodology and contains no data, and code provided in the supplementary material allows reproduction of all methods.

1. 1. Altman N
   2. Krzywinski M

   (2017) Points of significance: Interpreting P values

   Nature Methods 14:213–215.

   https://doi.org/10.1038/nmeth.4210

   • Google Scholar
2. 1. Baer BR
   2. Gaudino M
   3. Charlson M
   4. Fremes SE
   5. Wells MT

   (2021a) Fragility indices for only sufficiently likely modifications

   PNAS 118:e2105254118.

   https://doi.org/10.1073/pnas.2105254118

   • PubMed
   • Google Scholar
3. 1. Baer BR
   2. Gaudino M
   3. Fremes SE
   4. Charlson M
   5. Wells MT

   (2021b) The fragility index can be used for sample size calculations in clinical trials

   Journal of Clinical Epidemiology 139:199–209.

   https://doi.org/10.1016/j.jclinepi.2021.08.010

   • PubMed
   • Google Scholar
4. 1. Besançon L
   2. Bik E
   3. Heathers J
   4. Meyerowitz-Katz G

   (2022) Correction of scientific literature: too little, too late!

   PLOS Biology 20:e3001572.

   https://doi.org/10.1371/journal.pbio.3001572

   • PubMed
   • Google Scholar
5. 1. Bomze D
   2. Meirson T

   (2019) A critique of the fragility index

   The Lancet. Oncology 20:e551.

   https://doi.org/10.1016/S1470-2045(19)30582-0

   • PubMed
   • Google Scholar
6. 1. Colquhoun D

   (2014) An investigation of the false discovery rate and the misinterpretation of p-values

   Royal Society Open Science 1:140216.

   https://doi.org/10.1098/rsos.140216

   • PubMed
   • Google Scholar
7. 1. Das S
   2. Xaviar S

   (2020) Calculation of the fragility index of randomized controlled trials in epilepsy published in twelve major journals

   Epilepsy Research 159:106258.

   https://doi.org/10.1016/j.eplepsyres.2019.106258

   • PubMed
   • Google Scholar
8. 1. Del Paggio JC
   2. Tannock IF

   (2019a) The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis

   The Lancet. Oncology 20:1065–1069.

   https://doi.org/10.1016/S1470-2045(19)30338-9

   • PubMed
   • Google Scholar
9. 1. Del Paggio JC
   2. Tannock IF

   (2019b) A critique of the fragility index-authors ’ reply

   The Lancet. Oncology 20:e554.

   https://doi.org/10.1016/S1470-2045(19)30580-7

   • PubMed
   • Google Scholar
10. 1. Desnoyers A
    2. Nadler MB
    3. Wilson BE
    4. Amir E

    (2019) A critique of the fragility index

    The Lancet. Oncology 20:e552.

    https://doi.org/10.1016/S1470-2045(19)30583-2

    • PubMed
    • Google Scholar
11. 1. Errington TM
    2. Denis A
    3. Perfito N
    4. Iorns E
    5. Nosek BA

    (2021) Reproducibility in cancer biology: challenges for assessing replicability in preclinical cancer biology

    eLife 10:e67995.

    https://doi.org/10.7554/eLife.67995

    • Google Scholar
12. 1. Evaniew N
    2. Files C
    3. Smith C
    4. Bhandari M
    5. Ghert M
    6. Walsh M
    7. Devereaux PJ
    8. Guyatt G

    (2015) The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey

    The Spine Journal 15:2188–2197.

    https://doi.org/10.1016/j.spinee.2015.06.004

    • PubMed
    • Google Scholar
13. 1. Fanelli D

    (2009) How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data

    PLOS ONE 4:e5738.

    https://doi.org/10.1371/journal.pone.0005738

    • PubMed
    • Google Scholar
14. 1. Feinstein AR

    (1990) The unit fragility index: an additional appraisal of “ statistical significance ” for a contrast of two proportions

    Journal of Clinical Epidemiology 43:201–209.

    https://doi.org/10.1016/0895-4356(90)90186-s

    • PubMed
    • Google Scholar
15. 1. Grimes DR
    2. Bauch CT
    3. Ioannidis JPA

    (2018) Modelling science trustworthiness under publish or perish pressure

    Royal Society Open Science 5:171511.

    https://doi.org/10.1098/rsos.171511

    • PubMed
    • Google Scholar
16. 1. Grimes DR
    2. Currell FJ

    (2018) Oxygen diffusion in ellipsoidal tumour spheroids

    Journal of the Royal Society, Interface 15:20180256.

    https://doi.org/10.1098/rsif.2018.0256

    • PubMed
    • Google Scholar
17. 1. Grimes DR
    2. Heathers J

    (2021a) Association between magnetic field exposure and miscarriage risk is not supported by the data

    Scientific Reports 11:1–5.

    https://doi.org/10.1038/s41598-021-01391-3

    • PubMed
    • Google Scholar
18. 1. Grimes DR
    2. Heathers J

    (2021b) The new normal? redaction bias in biomedical science

    Royal Society Open Science 8:211308.

    https://doi.org/10.1098/rsos.211308

    • PubMed
    • Google Scholar
19. 1. Grimes DR
    2. Corry EMA
    3. Malagón T
    4. O’Riain C
    5. Franco EL
    6. Brennan DJ

    (2021c) Modeling cervical cancer screening strategies with varying levels of human papillomavirus vaccination

    JAMA Network Open 4:e2115321.

    https://doi.org/10.1001/jamanetworkopen.2021.15321

    • PubMed
    • Google Scholar
20. 1. Halsey LG
    2. Curran-Everett D
    3. Vowler SL
    4. Drummond GB

    (2015) The fickle P value generates irreproducible results

    Nature Methods 12:179–185.

    https://doi.org/10.1038/nmeth.3288

    • PubMed
    • Google Scholar
21. 1. Hill A
    2. Mirchandani M
    3. Pilkington V

    (2022) Ivermectin for covid-19: addressing potential bias and medical fraud

    Open Forum Infectious Diseases 9:ofab645.

    https://doi.org/10.1093/ofid/ofab645

    • PubMed
    • Google Scholar
22. 1. Ioannidis JPA

    (2005) Why most published research findings are false

    PLOS Medicine 2:e124.

    https://doi.org/10.1371/journal.pmed.0020124

    • PubMed
    • Google Scholar
23. 1. Itaya T
    2. Isobe Y
    3. Suzuki S
    4. Koike K
    5. Nishigaki M
    6. Yamamoto Y

    (2022) The fragility of statistically significant results in randomized clinical trials for covid-19

    JAMA Network Open 5:e222973.

    https://doi.org/10.1001/jamanetworkopen.2022.2973

    • PubMed
    • Google Scholar
24. 1. Krawczyk M

    (2015) The search for significance: a few peculiarities in the distribution of P values in experimental psychology literature

    PLOS ONE 10:e0127872.

    https://doi.org/10.1371/journal.pone.0127872

    • PubMed
    • Google Scholar
25. 1. Loken E
    2. Gelman A

    (2017) Measurement error and the replication crisis

    Science 355:584–585.

    https://doi.org/10.1126/science.aal3618

    • PubMed
    • Google Scholar
26. 1. Machado T
    2. Duarte GS
    3. Gonçalves N
    4. Ferreira JJ
    5. Costa J

    (2019) A critique of the fragility index

    The Lancet. Oncology 20:e553.

    https://doi.org/10.1016/S1470-2045(19)30581-9

    • PubMed
    • Google Scholar
27. 1. Ridgeon EE
    2. Young PJ
    3. Bellomo R
    4. Mucchetti M
    5. Lembo R
    6. Landoni G

    (2016) The fragility index in multicenter randomized controlled critical care trials

    Critical Care Medicine 44:1278–1284.

    https://doi.org/10.1097/CCM.0000000000001670

    • PubMed
    • Google Scholar
28. 1. Tignanelli CJ
    2. Napolitano LM

    (2019) The fragility index in randomized clinical trials as a means of optimizing patient care

    JAMA Surgery 154:74–79.

    https://doi.org/10.1001/jamasurg.2018.4318

    • PubMed
    • Google Scholar
29. 1. Walsh M
    2. Srinathan SK
    3. McAuley DF
    4. Mrkobrada M
    5. Levine O
    6. Ribic C
    7. Molnar AO
    8. Dattani ND
    9. Burke A
    10. Guyatt G
    11. Thabane L
    12. Walter SD
    13. Pogue J
    14. Devereaux PJ

    (2014) The statistical significance of randomized controlled trial results is frequently fragile: a case for a fragility index

    Journal of Clinical Epidemiology 67:622–628.

    https://doi.org/10.1016/j.jclinepi.2013.10.019

    • PubMed
    • Google Scholar
30. 1. Walter SD
    2. Thabane L
    3. Briel M

    (2020) The fragility of trial results involves more than statistical significance alone

    Journal of Clinical Epidemiology 124:34–41.

    https://doi.org/10.1016/j.jclinepi.2020.02.011

    • PubMed
    • Google Scholar

Author details

1. David Robert Grimes

   1. School of Physical Sciences, Dublin City University, Dublin, Ireland
   2. Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland

   Contribution

   Conceptualization, Software, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration

   For correspondence

   davidrobert.grimes@dcu.ie

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-3140-3278

• 628

  views

• 110

  downloads

• 3

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.